Rx for Biotech

In this podcast episode, Dr. Erandi De Silva discusses the hybrid approach to gene therapy development at Forge Biologics, Inc., an emerging leader in the contract development and manufacturing (CDMO) market for advanced regenerative medicine products. Dr. De Silva also discusses the unique approach to building a culture and diverse talent pool within the Columbus, Ohio biotech ecosystem.

Forge Biologics is on a mission to enable access to life-changing gene therapies and help bring them from idea into reality. In this podcast episode, we learn about trends in the gene therapy landscape and contract manufacturing from Co-Founder and CEO, Timothy Miller, PhD.

This podcast episode previews the key precision medicine and cellular therapy data being showcased at this year's American Association of Cancer Research annual meeting.

Allen Davidoff, PhD is the Founder and CEO of XORTX Therapeutics, Inc., a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. This podcast episodes looks at novel therapies in development that may extend kidney health.

This podcast episode provides a short recap of the day long workshop hosted by the FDA’s Office of Therapeutic Products (OTP) a new office within CBER. The goal of the workshop was to share knowledge and best practices from experts in the field of advanced manufacturing and analytical technologies (AMAT) for regenerative medicine therapies.

Innovative manufacturing technologies and alternative testing methods were discussed along with, challenges and best practices critical for chemistry, manufacturing, and controls (CMC) of cellular and gene therapies and tissue engineered medical products.

As Life Science companies grow, they become less efficient. In this podcast episode, Dr. Donald Davis explains what scaling challenges are and what companies can do to become more efficient using the process improvement tools of lean six sigma.

Anyone who has experimented with ChatGPT can get a sense of the potential of generative AI. AI powers driverless cars, spots signs of disease on medical images, finds an answer when you ask Alexa a question, and lets you unlock your phone with your face to talk to friends on the iPhone. Those are just a few ways AI already touches our lives, but there are many ways AI is being utilized in the pharma industry.

Applying AI to big data in pharma will reshape business models, streamline manufacturing, and enhance everything from early drug discovery and clinical trial data to supply chain applications and other market intelligence. It can also enable life sciences companies to be more personalized and authentic in how they engage with health care professionals, patients, and other stakeholders.

In this podcast episode, we review the five main applications for AI in biotech, pharma and healthcare.

In this podcast episode, we recap highlights from JPM Healthcare conference with Chris Dokomajilar from DealForma, Inc., and review 2023 outlook for Biopharma Dealmaking, Financing, and Partnerships.

To join live webinar on February 8th, 2023, use this link: https://us02web.zoom.us/j/6097872444

In this podcast episode, Chris provides a short preview of biotechnology and pharmaceutical companies to watch in 2023.

This podcast episode covers the highlights from this year’s American Society of Hematology Annual Meeting that took place in New Orleans in early December. There was enormous excitement for novel therapies for blood cancers and for diseases that previously had very high morbidity and mortality and now, because of novel treatment modalities in the field of hematology, like T cell engagers and CAR-T cell therapies, patients outcomes are being improved.